GENETIC-POLYMORPHISM (ARG353-]GLN) IN COAGULATION-FACTOR-VII GENE AND FACTOR-VII LEVELS (COAGULANT ACTIVITY, ANTIGEN AND BINDING ABILITY TO TISSUE FACTOR) IN 101 HEALTHY JAPANESE

被引：15

作者：

TAKAMIYA, O

机构：

[1] Department of Medical Technology, School of Allied Medical Sciences, Shinshu University

来源：

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION | 1995年 / 55卷 / 03期

关键词：

BINDING ABILITY OF FACTOR VII TO TISSUE FACTOR; FACTOR VII ACTIVITY; FACTOR VII ANTIGEN; GENETIC POLYMORPHISM; JAPANESE;

D O I：

10.3109/00365519509089615

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

We studied the frequency of the Msp I genotype (Gln353) for factor VII in 101 young healthy Japanese individuals, and the levels of factor VII-related procoagulant activity (FVII:c), antigen (FVII:ag) and binding ability to tissue factor (FVII-TF binding). The frequency of the allele coding for the factor VII Gln353 was 0.05 among this group. Individuals with genotype M1M1 had an FVII:c of 103.52 +/- 17.85% (mean +/- SD), FVII:ag of 102.50 +/- 18.42% (mean +/- SD) and FVII-TF binding of 101.03 +/- 22.22% (mean +/- SD). Triglyceride levels of subjects with the M1M1 genotype were 84.34 +/- 44.97 mg dl(-1) (mean +/- SD). FVII:c (50%), FVII:ag (45%) and FVII-TF binding (36%) from an individual with the M2M2 type was the lowest, with a triglyceride value of 39 mg dl(-1). On the other hand, individuals with the genotype M1M2 had an FVII:c of 75.57 +/- 9.61% (mean +/- SD), FVII:ag of 72.43 +/- 8.54% (mean +/- SD) and FVII-TF binding of 68.14 +/- 14.91% (mean +/- SD). FVII:c, FVII:ag and FVII-TF binding in individuals with the M1M2 and M2M2 genotypes were significantly lower than those in individuals with the M1M1 genotype.

引用

页码：211 / 215

页数：5

共 25 条

[1]

Dalaker K., Hjermann I., Prydz H., A novel form of factor VII in plasma from men at risk for cardiovascular disease, Br J Haematol, 61, pp. 315-322, (1993)

[2]

Hoffman C., Shah A., Sodums M., Hultin M., Factor VII activity state in coronary artery disease, J Lab Clin Med, 111, pp. 475-481, (1993)

[3]

Mann K., Factor VII assays, plasma triglyceride levels and cardiovascular disease risk, Arteriosclerosis, 9, pp. 783-784, (1993)

[4]

Suzuki T., Yamauchi K., Matsushita T., Furumichi T., Furui H., Tsuzuki J., Et al., Elevation in factor VII activity and mass in coronary artery disease of varying severity, Clin Cardiol, 14, pp. 731-736, (1993)

[5]

Connelly J.B., Roderick P.J., Cooper J.A., Meade T.W., Miller G.J., Positive association between self-reported fatty food consumption and factor VII coagulant activity, a risk factor for coronary heart disease, in 4246. middle-aged men, Thromb Haemost, 70, pp. 250-252, (1993)

[6]

Carvalho de Sausa J., Bruckert E., Giral P., Soria C., Truffert J., Mirshahi M.C., Et al., Plasma factor VII, triglyceride concentration and fibrin degradation products in primary hyperlipidemia: a clinical and laboratory study, Haemostasis, 19, pp. 83-90, (1993)

[7]

Orland M., Leri O., Macioce G., Mattia G., Ferri G.M., Factor VII in subjects at risk for thromboembolism: activation or increased synthesis? Haemostasis, 17, pp. 340-343, (1987)

[8]

Green F., Kelleher C., Wilkes H., Temple A., Humphries M.T., A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals, Arterioscler Thromb, 11, pp. 540-546, (1993)

[9]

Humphries S.E., Lane A., Dawson S., Green F.R., The study of gene-environment interactions that influence thrombosis and fibrinolysis, Arch Pathol Lab Med, 116, pp. 1322-1328, (1993)

[10]

Takamiya O., Funahashi S., Yoshioka K., Preparation of factor VII depleted plasma by immunoaffinity chromatography of insolubilised anti-factor VII, Med Lab Sci, 43, pp. 251-259, (1993)

← 1 2 3 →